Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rapport Therapeutics (Nasdaq: RAPP) announced management will present and participate in investor events in March 2026, including TD Cowen, Citizens Life Sciences, Leerink Global Healthcare, and Stifel Virtual CNS Forum. Dates and times are March 3, 10, 11 and 17, 2026 with live webcasts available.

Interested parties may access live and archived webcasts via the company’s Investors website.

BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to participate in the following upcoming investor events:

TD Cowen 46^th Annual Healthcare Conference (Boston, MA) – presentation and fireside chat on Tuesday, March 3, 2026, at 3:10-3:40 pm ET.

The Citizens Life Sciences Conference (Miami, FL) – presentation on Tuesday, March 10, 2026, at 2:15 pm ET.

Leerink Global Healthcare Conference (Miami, FL) – presentation on Wednesday, March 11, 2026, at 9:20 am ET.

Stifel 2026 Virtual CNS Forum – fireside chat on Tuesday, March 17, 2026, at 9:30 am ET.

Interested parties may access the live and archived webcasts of the presentations and fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com/.

About Rapport Therapeutics

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline is anchored by its epilepsy portfolio, including focal onset seizures and primary generalized tonic-clonic seizures, in addition to bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing/vestibular disorders.

Contact

Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com

FAQ

When will Rapport Therapeutics (RAPP) present at the TD Cowen 2026 conference?

Rapport will present on March 3, 2026 at 3:10-3:40 pm ET. According to the company, management will deliver a presentation and fireside chat; webcasts will be available live and archived on the company Investors site.

How can investors watch Rapport Therapeutics (RAPP) presentations in March 2026?

Investors can access live and archived webcasts via the company’s Investors website. According to the company, all presentations and fireside chats will be streamed and archived for later viewing on the Investors page.

What dates is Rapport Therapeutics (RAPP) scheduled to present at Citizens and Leerink conferences?

Rapport is scheduled for Citizens on March 10, 2026 at 2:15 pm ET and Leerink on March 11, 2026 at 9:20 am ET. According to the company, both events include investor presentations with webcast access.

Will Rapport Therapeutics (RAPP) participate in any virtual events in March 2026?

Yes. Rapport will take part in the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 9:30 am ET. According to the company, management will join a fireside chat with webcast availability for investors.

Where is the official webcast link for Rapport Therapeutics (RAPP) March 2026 presentations?

The official webcasts are available on the company’s Investors website (investors.rapportrx.com). According to the company, interested parties can view live streams and archived recordings under the Investors section.